SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001104659-18-070697
Filing Date
2018-11-30
Accepted
2018-11-29 21:34:07
Documents
6
Effectiveness Date
2018-11-30

Document Format Files

Seq Description Document Type Size
1 DEFA14A a18-40826_2defa14a.htm DEFA14A 48462
2 GRAPHIC g408262bci001.gif GRAPHIC 13801
3 GRAPHIC g408262bei001.gif GRAPHIC 248143
4 GRAPHIC g408262bei002.gif GRAPHIC 220221
5 GRAPHIC g408262bei003.gif GRAPHIC 120088
6 GRAPHIC g408262bei004.gif GRAPHIC 118685
  Complete submission text file 0001104659-18-070697.txt   1042837
Mailing Address 399 THORNALL STREET FIRST FLOOR EDISON NJ 08837
Business Address 399 THORNALL STREET FIRST FLOOR EDISON NJ 08837 732-902-4000
ContraVir Pharmaceuticals, Inc. (Filer) CIK: 0001583771 (see all company filings)

IRS No.: 462783806 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-36856 | Film No.: 181209741
SIC: 2834 Pharmaceutical Preparations